Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
AAV based gene therapy | 1 |
Recombinant polypeptide | 1 |
Target |
Mechanism CD4 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GPR65 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Start Date31 Jan 2024 |
Sponsor / Collaborator |
Start Date29 Nov 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
LM49 ( CD4 ) | Diabetic Nephropathies More | Phase 1 |
CN117510593 ( PDL1 ) | Neoplasms More | Discovery |
CN117771392 ( GPR65 ) | Nervous System Diseases More | Discovery |
DA-CH5 ( GIPR x GLP-1R ) | Parkinson Disease More | Pending |
DA-JC1 ( GIPR x GLP-1R ) | Alzheimer Disease More | Pending |